A Study of LY3041658 in Adults With Hidradenitis Suppurativa

Summary

The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).

Timeline

Start

2020-08-26

Primary completion

2022-03-15

Completion

2022-10-13

Publications

• Forman S, Patel DR, Kimball AB, Jaleel T, Laquer V, Wang T, Zhang Y, Shen L, Nirula A, Klekotka P. A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa. J Am Acad Dermatol. 2026 Feb;94(2):530-538. doi: 10.1016/j.jaad.2025.10.015. Epub 2025 Oct 6.

Drugs

Indications